Secukinumab en HS

Many Patients With Hidradenitis Suppurativa May Respond To Secukinumab, Study Suggests.

MedPage Today (9/18, Bankhead) reports researchers found that "more than three fourths of patients with longstanding hidradenitis suppurativa (HS) responded to treatment with" Cosentyx (secukinumab). The findings were presented at the European Academy of Dermatology and Venereology meeting.

Sent from my iPhone

Benjamin Hidalgo-Matlock
Skin Care Physicians of Costa Rica

Clinica Victoria en San Pedro: 2224-0654
Momentum Escazu: 2101-9574

Please excuse the shortness of this message, as it has been sent from
a mobile device.